Thursday, February 7, 2019; 8:45 AM – 10:15 AM
Section outline
-
Lecture: Measuring Outcomes and Adverse Effects
Defining adverse events; elicited vs. volunteered; nuisance adverse events; pitfalls of attribution of cause; FDA adverse events classifications.
Faculty: Dennis Black
Location: Mission Hall 1400
-
Psaty BM, Lumley T. Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs. JAMA. 2008 Mar 26;299(12):1474-6. File
-
Bent S, et al. Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med. 2006 Feb 21;144(4):257-61. File
-
Miller, PD., et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis a randomized clinical trial. Jama 316.7 (2016) 722-733. File
-
Black, DM., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New England Journal of Medicine 356.18 (2007) 1809-1822. File